Schenell Biopharmaceutical jumps into biosimilars
Published: 2010-01-18 06:56:00
Updated: 2010-01-18 06:56:00
Schenell Biopharmaceutical Inc. is jumping into a blue ocean for newer versions of innovator biopharmaceutical products, biosimilars, following an agreement with Aprogen Co. to take over all marketing rights of biosimilar products, such as Rituxan and Remicade.
Schenell said in a regulatory fi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
